I wake up before the sun and start building the day. First the tea. Then the medication list. Then the careful arrangement of pillows…
Myeloma
Bristol Myers Squibb‘s experimental cell therapy arlocabtagene autoleucel (arlo-cel) may help control myeloma that has returned or failed…
I sit in the doctor’s office translating between two languages. The oncologist speaks in medical terms — “progression-free survival,” “bispecific antibody therapy,” “osteolytic lesions,” “minimal…
Since the late 1940s, when the first chemotherapies were introduced, advances in treatment for blood cancers have resulted in an estimated 25.8 million life-years…
There are many treatments now available for multiple myeloma. Quadruplet therapy, bispecific therapy, CAR T-cell therapy, and cereblon E3 ligase modulators (CELMoDs)…
September is Blood Cancer Awareness Month, and advocates around the world are joining together to shine a light on blood cancer and fundraise to…
A new CAR T-cell therapy designed to target multiple myeloma while sparing healthy immune cells has been given to its first patient in a…
I hand my mum her morning tea and notice the way she adjusts her grip on the cup without saying anything. In that small movement,…
One of my very first columns asked, “Where’s my secret decoder ring?” That was because it’s easy to become overwhelmed by the many names…
Treating multiple myeloma with a Darzalex (daratumumab)-based combination may lead to a faster and longer-lasting response than a standard combination regimen using lenalidomide (sold…
Recent Posts
- Infection risk shifts over time with both CAR T and bispecific antibody therapy
- Building the quiet architecture of a caregiving day
- New CAR T-cell therapy shows promise in tough myeloma cases
- CAR T-cell therapy before surgery boosts glioblastoma control in mice
- Gynecologic Cancer Awareness Month urges education, action, and support